Download PDF
Hamostaseologie 2001; 21(01): 1-4
DOI: 10.1055/s-0037-1619497
Original article
Schattauer GmbH

Zytostatische Chemotherapie: Einflüsse auf das Hämostasesystem

Cytostatic chemotherapy: influences on the hemostatic system
A. Giagounidis
1   Klinik für Hämatologie, Onkologie und klinische Immunologie der Heinrich-Heine-Universität Düsseldorf
,
U. Germing
1   Klinik für Hämatologie, Onkologie und klinische Immunologie der Heinrich-Heine-Universität Düsseldorf
,
R. Haas
1   Klinik für Hämatologie, Onkologie und klinische Immunologie der Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
Further Information

Publication History

Publication Date:
27 December 2017 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Gerinnungsstörungen bei bösartigen Erkrankungen sind durch vielfältige Wechselwirkungen zwischen Tumorzellen, deren Produkten und dem Organismus bedingt. Diese führen zu einer verschieden stark ausgeprägten Beeinträchtigung der Hämostase und können dadurch Thromboembolien oder Blutungen verursachen. Die zugrundeliegenden Mechanismen der Einflussnahme von Zytostatika auf das Gerinnungssystem werden beschrieben. Die Daten zur prophylaktischen Antikoagulation während Chemotherapie sind widersprüchlich.

Summary

Coagulation disorders in malignancies are due to complex interactions between tumor cells, their products and the organism leading to various degrees of impairment of haemostasis. This can cause either thromboembolism or bleeding. The risk of such complications increases during chemotherapy. The underlying mechanisms influencing the haemostatic system influenced by cytostatic agents are described. Data supporting the use of prophylactic anticoagulation in patients with malignancy and during chemotherapy are inconsistent.

Schlüsselwörter

Hämostase - Zytostatische Chemotherapie

Keywords

Haemostasis - cytostatic chemotherapy
 

  • Literatur

  • 1 Alberts S, Bretscher M, Wiltsie J. et al. Thrombosis related to the use of l-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement. Leukemia and Lymphoma 1999; 32: 489-96.
    PubMedSearch in Google Scholar
  • 2 Ayash L. Hepatic complications of bone marrow transplantation. In: Armitage J, Antman K. (Edit.). High-dose cancer therapy: pharmacology, hematopoietins, stem cells. Baltimore, Maryland: Williams & Wilkins; 1992: 488-93.
    Search in Google Scholar
  • 3 By G. v. Tempelhoff M Blood coagulation during adjuvant epirubicin/cyclophosphamid chemotherapy in patients with primary operable breast cancer. J Clin Oncology 1996; 14: 2560-8.
    CrossrefPubMedSearch in Google Scholar
  • 4 Cozzolino F, Torcia M. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in akute nonlymphoblastic leucemia. Am J Med 1988; 84: 240-50.
    CrossrefPubMedSearch in Google Scholar
  • 5 Falanga A, Rickles R. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25 (02) 173-82.
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis 1998; 28 (Suppl. 03) 50-60.
    PubMedSearch in Google Scholar
  • 7 Gabazza E, Taguchi O. et al. Alteration of coagulation and fibrinolysis systems after multi-drug anti-cancer therapy for lung cancer. Eur J cancer 1994; 30A: 1276-81.
    PubMedSearch in Google Scholar
  • 8 Knöbl P. Die akute Promyelozytenleukämie. In: Matthias R, Rasche H. (Hrsg). Onkologie und Hämostasesystem. Stuttgart: Schattauer; 1999: 201-15.
    Search in Google Scholar
  • 9 Lee A, Levine M. The thombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999; 25 (02) 137-45.
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Levine M, Hirsh J, Gent M. Double blind randomized trial of very low-dose warfarin for the prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
    CrossrefPubMedSearch in Google Scholar
  • 11 Lorenzet R, Peri G. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissue. Blood 1983; 62: 2721-3.
    PubMedSearch in Google Scholar
  • 12 Mattioli Belmonte M, Gugliotta L, Delvos U. et al. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase. Haematologica 1991; 76: 209-14.
    PubMedSearch in Google Scholar
  • 13 Nowak-Göttl U, Rath B, Binder M. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy. Haematologica 1995; 80: 451-3.
    PubMedSearch in Google Scholar
  • 14 Rickles R, Levine M. Hemostatic alterations in cancer patients. Cancer Met Rev 1992; 11: 237-48.
    CrossrefPubMedSearch in Google Scholar
  • 15 Steffens C, Ulrich D, Bruhn HD. Einfluss der palliativen Chemotherapie kolorektaler Karzinome mit 5-FU und Leukovorin auf das Fibrinolysesystem. In: Matthias R, Rasche H. (Hrsg). Onkologie und Hämostasesystem. Stuttgart: Schattauer; 1999: 263-7.
    Search in Google Scholar
  • 16 Walsh J, Wheeler H, Geczy L. Modulation of tissue factor on human monocytesby cisplatin and adriamycin. Brit J Haemat 1992; 81: 480-8.
    CrossrefPubMedSearch in Google Scholar
  • 17 Van de Walter L, Tracy P. Tumor cell generation of thrombin via prothrombinase assembly. Cancer Res 1985; 45: 5521.
    PubMedSearch in Google Scholar